RBC Capital raised the firm’s price target on Alpine Immune Sciences to $41 from $29 and keeps an Outperform rating on the shares. The company’s povetacicept profile has been further strengthened by recent positive data from competitors and amplified by key opinion leaders’ interest in BAFF/APRIL’s B cell-depletion mechanism as a direct attack on IgA nephropathy’s root cause, the analyst tells investors in a research note. RBC adds its price target increase is due to povetacicept’s strong competitive positioning, the potential for greater validation by upcoming updates in the first half of the year, and a comfortable runway into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALPN:
- Alpine Immune Sciences assumed with an Outperform at Oppenheimer
- Wolfe starts Alpine at Outperform, says bullish on de-risked mechanism
- Alpine Immune Sciences initiated with an Outperform at Wolfe Research
- Alpine Immune Sciences Expands Investor Base with Warrant Exercises
- Biotech Alert: Searches spiking for these stocks today